Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.

Abstract

Trifunctional antibodies (trAbs) are promising novel anticancer biologics with a particular mode of action capable of linking innate with adaptive immunity. Based on their unique structure, trifunctional IgG-like heterodimeric antibodies, consisting of nonhuman mouse and rat immunoglobulin halves are able to redirect T lymphocytes, as well as accessory cells, to the tumor site. This recruitment of immune cells is accompanied by cellular activation events elicited by anti-CD3, as well as Fcγ-receptor engagement of trAbs supported by a proinflammatory Th1-biased cytokine milieu. All necessary immunological factors required for long-term vaccination-like effects are stimulated along trAb-mediated therapeutic interventions. Thus, the concerted interplay of antibody-dependent cellular cytotoxicity plus the polyclonal T-cell cytotoxicity and Fcγ-receptor-driven induction of long-lasting immune responses after the initial tumor cell elimination represent the major hallmarks of trAb-mediated treatment of malignant diseases.

• Authors: Juergen Hess, Peter Ruf, Horst Lindhofer
• Journal: Future oncology (London, England) (Future Oncol) Vol. 8 Issue 1 Pg. 73-85 (Jan 2012) ISSN: 1744-8301 [Electronic] England
• PMID: 22149036 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies
• Antineoplastic Agents
• Cancer Vaccines

Topics

• Adaptive Immunity
• Animals
• Antibodies (immunology, therapeutic use)
• Antineoplastic Agents (immunology, therapeutic use)
• Biopharmaceutics
• Cancer Vaccines (immunology, therapeutic use)
• Clinical Trials as Topic
• Humans
• Immunity, Innate
• Neoplasms (drug therapy, immunology)
• T-Lymphocytes (immunology)